Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24854468 | 0.74 | GLB1 (0.31) | — | |
| SCHEMBL20994691 | 0.74 | BCHE (0.41) | BCHECHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL23936859 | 0.73 | BCHE (0.45) | BCHECHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL24854467 | 0.72 | — | — | |
| SCHEMBL24854464 | 0.71 | — | — | |
| SCHEMBL27285927 | 0.70 | BCHE (0.43) | BCHECHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL21423962 | 0.70 | BCHE (0.49) | BCHECHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL24854465 | 0.68 | — | — | |
| SCHEMBL30747896 | 0.68 | BCHE (0.41) | BCHECHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL20996039 | 0.68 | BCHE (0.44) | BCHECHRNB2CHRNA4CHRNA7CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-07 | — | — | US | disclosed |
| US-20190142961-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | BCHE 3849/4885CHRNB2 4483/4885CHRNA4 4776/4885 |
| US-20190142961-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | ASH1L, ASH2L, DOT1L | BCHE 3849/4885CHRNB2 4483/4885CHRNA4 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.